Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-10-17
2006-10-17
Swartz, Rodney P (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S009100, C424S009200, C424S093100, C424S093200, C435S440000, C435S471000, C435S243000, C435S253100, C536S023100, C536S023700, C536S023400, C536S024320
Reexamination Certificate
active
07122195
ABSTRACT:
This invention relates to recA mutant mycobacteria, particularly mutants of mycobacterial species which are members of theMycobacterium tuberculosiscomplex, such asM. bovisBCG andM. tuberculosis. These mutant mycobacteria are useful as immunotherapteutic agents and vaccines for the treatment of a range of disorders, including tuberculosis.
REFERENCES:
Kumar et al; “Functional Characterization of the Precursor and Spliced Forms of RecA Protein of Mycobacterium Tuberculosis”; Biochemistry, vol. 35, Feb. 13, 1996, pp. 1793-1802. XP00107081.
Papavinasasundarm et al; “Construction and Complementation of a recA Deletion Mutant of Mycobacterium Smegmatis Reveals That the Intein in Mycobacterium Tuberculosis recA Does Not Affect RecA Function”; Molecular Microbiology, vol. 30, No. 3, 1998, pp. 525-534, XP002201173.
Frischkorn et al; “Investigation of Mycobacterial recA Function: Protein Introns in the RecA of Pathogenic Mycobacteria do not Affect Competency For Homologous Recombination”; Molecular Microbiology, vol. 29, No. 5, 1998, pp. 1203-1214, XP000961254.
McFadden; “Recombination in Mycobacteria”; Molecular Microbiology, vol. 21, No. 2, 1996, pp. 205-211, XP001070919.
Sander et al; “Mycobacterium Bovis BCG recA Deletion Mutant Shows Increased Susceptibility to DNA-Damaging Agents But Wild-Type Survival N a Mouse Infection Model”; Infection and Immunity, vol. 69, No. 6, Jun. 2001, pp. 3562-3568, XP001070859.
Boettger Eric
Colston, legal representative Kay
Sander Peter
Springer Burkhard
Boettger Erik C.
Nixon & Vanderhye P.C.
Swartz Rodney P
LandOfFree
Mutant mycobacteria for use in therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutant mycobacteria for use in therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutant mycobacteria for use in therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3681715